Abbomax · Newsroom
Scientists at AbboMax developed antibodies against PINK1 and Parkin to study Parkinson’s disease
A panel of PINK1 and Parkin antibodies was developed at Abbomax to investigate Parkinson’s disease (PD). These phosphospecific and paired antibodies would be the useful tools for studies of PINK/Parkin pathways and signaling in PD.May 7, 2019